非急诊冠状动脉旁路移植术中阵发性与持续性房颤管理策略的长期结局
基于STS成人心脏外科数据库(2011-2022)链接Medicare索赔数据,分析59,331例接受单纯CABG的阵发性或持续性房颤患者的房颤治疗趋势及长期生存。结果显示近半数患者未接受治疗,心外膜消融与更优长期生存相关,所有治疗策略均与较低卒中风险相关。
要点
- 近半数(51.0%)接受CABG的房颤患者未接受任何房颤治疗。
- 心外膜消融与不治疗相比,长期死亡率更低。
- 所有治疗策略均与不治疗相比降低卒中风险和房颤再入院风险。
核心结论
- 近半数接受CABG的房颤患者未接受治疗,心外膜消融与更优长期生存相关,所有治疗策略均与较低卒中风险相关。
研究设计与样本
- 回顾性队列研究,数据来自STS成人心脏外科数据库(2011-2022)并链接Medicare索赔数据,纳入59,331例接受单纯CABG的阵发性或持续性房颤患者。
- 按房颤治疗分为四组:无治疗、仅左心耳封堵(LAAO)、心外膜消融(EA)、心内消融(IA)。
- 主要终点为全因死亡率,采用Kaplan-Meier法和Cox回归分析;次要终点包括永久起搏器植入、卒中及房颤、出血或心衰再入院,采用竞争风险回归(死亡为竞争事件)。
主要发现
- 59,331例患者中,阵发性房颤占71.0%,从2011年的56.6%增至2022年的79.6%。
- 房颤治疗分布:无治疗51.0%,仅LAAO 15.3%,EA 25.4%,IA 8.2%;总治疗率从31.8%升至68.8%,主要由LAAO增加驱动(1.2%至30.8%)。
- 持续性房颤患者死亡率高于阵发性房颤患者(P < .001)。
- EA与不治疗相比显示更低死亡率。
- IA与更高起搏器植入率相关(6.0% vs 其他组3.2%-3.4%;P < .001)。
临床怎么用
- 接受CABG的阵发性或持续性房颤患者中,应考虑实施心外膜消融以改善长期生存。
- 所有房颤治疗策略(LAAO、EA、IA)均与降低卒中风险和房颤再入院风险相关,可根据患者情况选择。
- 选择心内消融时需权衡起搏器植入风险增高(6.0% vs 3.2%-3.4%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of atrial fibrillation (AF) at the time of coronary artery bypass grafting (CABG) is a class 1 recommendation. This study evaluated trends in AF management and their association with long-term survival. METHODS: Patients with paroxysmal or persistent AF who underwent isolated CABG were identified from The Society of Thoracic Surgeons Adult Cardiac Surgery Database (2011-2022) with linkage to Medicare claims for long-term outcomes. Patients were stratified by AF treatment: none, left atrial appendage occlusion (LAAO) only, epicardial ablation (EA), or intracardiac ablation (IA). The primary end point was all-cause mortality; secondary end points included permanent pacemaker placement, stroke, and readmission for AF, bleeding, or heart failure. Long-term mortality was assessed using Kaplan-Meier methods and Cox regression. Nonfatal outcomes were assessed using competing-risk regression with death as the competing event. RESULTS: Among 59,331 patients, 71.0% had paroxysmal AF, increasing from 56.6% (2011) to 79.6% (2022). AF treatment included none (51.0%), LAAO only (15.3%), EA (25.4%), and IA (8.2%). AF treatment increased from 31.8% to 68.8%, driven by LAAO (1.2%-30.8%). Patients with persistent AF had higher mortality than patients with paroxysmal AF (P < .001). EA showed lower mortality compared with no treatment. IA was associated with higher pacemaker implantation (6.0% vs 3.2%-3.4% in other groups; P < .001). Compared with no treatment, all treatment groups had lower stroke risk (subdistribution hazard ratio, 0.64-0.79; P < .001) and lower AF readmission (subdistribution hazard ratio, 0.85-0.89; P < .05). CONCLUSIONS: Nearly one-half of patients with AF who underwent CABG receive no treatment. Epicardial ablation was associated with superior long-term survival, and all strategies with were associated lower stroke risk.
引用
- Hawkins RB, Kubi B, Strobel RJ, et al. Long-Term Outcomes of Paroxysmal and Persistent Atrial Fibrillation Management Strategy During Nonemergent Coronary Artery Bypass Surgery. Ann Thorac Surg. 2026. PMID: 42134563. doi:10.1016/j.athoracsur.2026.04.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。